IMMU

[Michael]

IMMU sold at 2.54.

This is close call but it seems like the sellers at 2.55 is having the upper hand today so we will bail out here.

IMMU is still a great stock so we will keep it on out watch list.

[la-onda]

Michael,
IMMU is back 

still on your watchlist?


cheers
O.

[la-onda]

Michael,
what´s up?

Immunomedics to Be Awarded U.S. Patent for the Treatment of B-Cell Lymphomas, Leukemias and Autoimmune Diseases
Thursday December 7, 11:30 am ET

MORRIS PLAINS, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU - News), a leading biopharmaceutical company focused on developing monoclonal antibodies, today announced that U.S. patent 7,151,164 will issue on December 19, 2006, covering methods for treating B-cell disorders using the Company's monoclonal antibody that binds to the CD20 antigen present on B-lymphocytes. The allowed claims cover the use of the Company's product, hA20, which is a humanized anti-CD20 monoclonal antibody for the treatment of B-cell lymphomas, leukemias and autoimmune diseases.


"This patent strengthens our position for the advancement of a new anti-CD20 antibody for the treatment of B-cell mediated diseases. Our hA20 antibody has demonstrated a number of features that we believe differentiate it from other anti-CD20 antibodies, such as more rapid administration, less adverse events during infusion and activity at lower doses," commented Cynthia L. Sullivan, Company President and CEO. "We are particularly interested in the efficacy at lower doses, because this could permit evaluation of different formulation, such as subcutaneous injections, which could be more convenient and economical for doctors and patients," she further remarked.

About hA20

hA20 was constructed using the same human donor frameworks and methods employed to make the Company's anti-CD22 antibody, epratuzumab. Epratuzumab has been studied in over 300 non-Hodgkin's lymphoma (NHL) patients and can be infused within an hour. hA20 displays similar binding avidity, specificity, and mechanisms of action as rituximab, but has structural differences, and to date, shows an excellent safety and tolerability profile, even when infused within 2 hours. At a single low dose of 120 mg/m2, hA20 depleted circulatory B-cells, and produced high complete responses in recurrent NHL patients with prior rituximab treatments when given once weekly over 4 concurrent weeks. Doses between 120 and 750 mg/m2 were evaluated in this multi-center clinical trial. To-date, no patients have shown an elevated immune response to repeated injections of hA20. An update of the ongoing Phase I study of hA20 will be presented next week at the 2006 annual meeting of the American Society of Hematology in Orlando, FL.

[Amarens]

Don't know what is up but sure like it  .

Don't want to see my profits run away again. Might be tight but I put a stop at $ 3,-

It's up premarket 

Amarens

[nullzero]

Lots of buying volume something is up for IMMU like to hear what others are saying. Here is a updated chart.

[la-onda]

I can´t find the news for the excellent chart action 

Setravis, please MERGE the 3 threads to one!
thanks in advance
Oliver

[setravis]

(IMMU).......
PRESENTS POSITIVE PRECLINICAL DATA: Immunomedics, Inc. (IMMU) announced that its
humanized anti-CD74 antibody, milatuzumab, showed promising therapeutic activity for B-cell
lymphoma in animal models. This activity can be enhanced when combined with anti-CD20 antibodies.
These preclinical results were presented at the AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer Therapeutics in San Francisco, CA. Milatuzumab was
tested in comparison to and in combination with veltuzumab, a humanized anti-CD20 antibody
from Immunomedics, in mice bearing human B-cell lymphoma transplants. Median survival time
(MST) for untreated animals was 36 days. Veltuzumab extended MST to 70 days, while milatuzumab
treatment increased survival further to 90.5 days. However, when both antibodies were
combined, MST improved significantly to 113 days.